A Study to Evaluate ALN-2232 in Participants With Obesity

NCT07463846 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the safety of the experimental drug ALN-2232 in adults who have obesity.

Status Recruiting Currently enrolling participants.

Phase Phase1, Phase2

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 156 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2026-03 · est. completion 2028-03

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT07463846 ↗

Description as written by the study sponsor.

The purpose of this study is to: * evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity

Treatments tested

ALN-2232 Drug

ALN-2232 will be administered subcutaneously (SC)
Placebo Drug

Placebo will be administered SC
Tirzepatide Drug

Tirzepatide will be administered SC

Main thing measured	Part A: Frequency of Adverse Events (AEs)
Sponsor	Alnylam Pharmaceuticals
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07463846 ↗